Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Cong...
September 26 2019 - 6:05PM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced it will host a
conference call and audio webcast on Monday, September 30 at 5:30
a.m. Pacific Time (8:30 a.m. ET) to review data from the Calithera
clinical program presented at the European Society for Medical
Oncology (ESMO) Congress 2019. Calithera management will review
data from the ENTRATA study evaluating the glutaminase inhibitor
telaglenastat and data presented on INCB001158, an oral arginase
inhibitor.
Details of the ESMO 2019 oral late-breaking presentation
for telaglenastat are as follows:
Date: Saturday, September 28, 2019, 8:30
a.m. CET, Barcelona Auditorium Session Title:
Proffered Paper 1-Genitourinary tumors, non-prostate
Abstract Title: "ENTRATA: Randomized,
double-blind, phase 2 study of telaglenastat (CB-839) + everolimus
vs. placebo + everolimus in patients with advanced/metastatic renal
cell carcinoma (RCC)." R. Motzer, et al.
Abstract: LBA54 Presenter:
Chung-Han Lee, M.D., PhD of the Memorial Sloan Kettering Cancer
Center
Details of the oral presentation for INCB001158 are as
follows:
Date: Sunday, September 29, 2019, 4:30
p.m. CET, Malaga Auditorium Session Title:
Proffered Paper – Developmental therapeutics Abstract
Title: "Phase 1 study of the arginase inhibitor INCB001158
(1158) alone and in combination with pembrolizumab in patients with
advanced/metastatic solid tumors." A. Naing, et al.
Abstract: 440O Presenter:
Aung Naing, M.D., FACP, Associate Professor, Department of
Investigational Cancer Therapeutics, Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center
Link: Abstract is available at
https://www.esmo.org/Conferences/ESMO-Congress-2019
To participate in the Calithera ESMO 2019 Call, please dial
(855) 783-2599 (domestic) or (631) 485-4877 (international) five
minutes prior to the start of the call and provide the conference
ID 1469186. To access the live audio webcast or the subsequent
archived recording, visit the Investors section of the Calithera
website at www.calithera.com. The webcast will be recorded and
available for replay on Calithera’s website for 30 days.
About Telaglenastat
Telaglenastat is an investigational first-in-class, novel
glutaminase inhibitor specifically designed to block glutamine
consumption in tumor cells. RCC tumors commonly exhibit metabolic
alterations that increase their dependence on glutamine. In
preclinical studies, telaglenastat produced synergistic antitumor
effects when used in combination with standard-of-care RCC
therapies. On June 17, 2019, Calithera announced that a randomized
Phase 2 trial of telaglenastat plus everolimus versus everolimus
plus placebo (ENTRATA) met its primary endpoint of improving
progression free survival, demonstrating proof of concept for
telaglenastat in patients with advanced RCC. The ongoing CANTATA
trial is a global, randomized, double-blind trial designed to
evaluate the safety and efficacy of telaglenastat plus cabozantinib
versus placebo plus cabozantinib in patients with advanced or
metastatic RCC.
About INCB001158 (CB-1158)
INCB001158 (CB-1158) is an investigational first-in-class, novel
small molecule arginase inhibitor. Arginase is an enzyme that
suppresses the immune-mediated destruction of tumors by depleting
levels of a key amino acid, L-arginine, from the tumor
microenvironment. A number of cell types in the tumor
microenvironment, including myeloid-derived suppressor cells,
macrophages, and neutrophils, can secrete arginase. L-arginine
deprivation can act via nutrient sensor pathways to exert several
suppressive effects on T-cell function, inhibiting proliferation,
decreasing cytokine production, and diminishing expression of the
T-cell receptor CD3ζ chain. Arginase activity may thus impair
T-cell mediated anti-tumor responses. INCB001158 is being developed
in a global collaboration with Incyte Corporation.
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical
company pioneering the discovery and development of targeted
therapies that disrupt cellular metabolic pathways to
preferentially block tumor cells and enhance immune-cell activity.
Driven by a commitment to rigorous science and a passion for
improving the lives of people impacted by cancer and other
life-threatening diseases, Calithera is advancing a pipeline of
first-in-clinic, oral therapeutics to meaningfully expand treatment
options available to patients. Calithera is headquartered in South
San Francisco, California. For more information about Calithera,
please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the safety,
tolerability and efficacy of Calithera’s product candidates, the
overall advancement of Calithera’s product candidates in clinical
trials, the unmet need in the treatment of patients with advanced
disease, and Calithera’s plans to continue development of its
product candidates. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such
product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with
respect to any of the foregoing matters may have a negative effect
on Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found
in Calithera's most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, and other periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences,
Incorporated
CONTACT:
Jennifer McNealeyir@Calithera.com650-870-1071
MEDIA CONTACT: Hannah Hurdle
hannahhurdle@sambrown.com 805-338-4752
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024